Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation


About this study

The purpose of the study is to evaluate the safety and effectiveness of the ReliantHeart HeartAssist 5® VAD System in patients listed for heart transplantation and at risk of death from refractory end-stage heart failure.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Able to sign Informed Consent.
  2. Age ≥ 18
  3. Body Surface Area (BSA) ≥ 1.2 m2.
  4. Cardiac transplant candidate, defined as: Listed for cardiac transplant, and designated by the institution's multidisciplinary transplant committee as appropriate forLVAD Bridge-to-Transplantation therapy, or Designated by the institutions's multidisciplinary transplant committee as: 1) an appropriate candidate for LVAD Bridge-to transplant therapy, and 2) An inappropriate candidate for LVAD destination therapy
  5. LVAD implantation has been approved by the institution's multidisciplinary transplant committee.
  6. Patient is NYHA Class IV.
  7. Able to return to the clinical site for all routine follow up visits.

Exclusion Criteria:

  1. Cardiothoracic surgery within 30 days prior to enrollment.
  2. Acute Myocardial Infarction within 14 days prior to enrollment.
  3. Prior cardiac transplantation, left ventricular reduction surgery, cardiomyoplasty or left ventricular assist device.
  4. Mechanical, animal, or human tissue heart valve.
  5. History of untreated abdominal or thoracic aortic aneurysm > 5 cm.
  6. On ventilator support for > 72 hours within four days immediately prior to enrollment.
  7. Ongoing mechanical circulatory support other than an intra-aortic balloon pump (IABP).
  8. Proven history of pulmonary embolism within 90 days of enrollment.
  9. Moderate to severe aortic insufficiency as determined by echocardiogram without plans for correction during pump implantation surgery.
  10. Requires aortic, mitral, tricuspid or pulmonary valve replacements (including Bioprosthetic valves) or left ventricular (LV) aneurysm resection.
  11. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelets <100,000, INR > 1.6 or PTT > 2.5 times control in the absence of anticoagulation therapy)
  12. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support OR extracorporeal membrane oxygenation (ECMO) at the time of implantation OR right atrial pressure > 20 mmHg while on multiple inotropes.
  13. Significant renal dysfunction defined as > 3.5 mg/dl or requires hemo or peritoneal dialysis for renal failure (excluding ultra-filtration for fluid removal).
  14. Evidence of intrinsic hepatic disease defined as liver enzyme values (AST, ALT and LDH that are > 3 times the upper limit of normal) OR a total bilirubin > 3 mg/dl OR biopsy proven liver cirrhosis or portal hypertension.
  15. Pregnancy
  16. Active systemic infection prior to study enrollment not yet resolved by treatment. Active Systemic Infection is defined by any one of the following in spite of antibiotic, antiviral or antifungal treatment: 2 or more consecutive positive cultures; elevated temperature > 37.2 (°C) and white blood cell count > 11.0 (103/ml); hypotension, tachycardia and generalized malaise.
  17. Stroke within 90 days prior to enrollment OR patient has a history of cerebral vascular disease with > 80% extra cranial stenosis documented by carotid Doppler study during transplant evaluation
  18. Modified Rankin Scale score of ≥ 2 or has any neurologic disability as confirmed by imaging (CT or MRI).
  19. Significant lower extremity peripheral vascular disease accompanied by rest pain or leg ulceration.
  20. Intolerant to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status.
  21. Psychiatric disorder, or other psychosocial behavior that is likely to impair compliance with the study protocol.
  22. Receiving therapy with an investigational intervention or participating in any other clinical investigation at the time of enrollment.
  23. Condition, other than heart failure, that may limit survival to less than three (3) years and/or would exclude cardiac transplantation.
  24. Unwilling or unable to comply with any study requirement.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

John Stulak, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer